Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

IRIX vs ATRC vs EW vs HOLX vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IRIX
IRIDEX Corporation

Medical - Devices

HealthcareNASDAQ • US
Market Cap$18M
5Y Perf.-42.8%
ATRC
AtriCure, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$1.33B
5Y Perf.-45.0%
EW
Edwards Lifesciences Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$46.10B
5Y Perf.+6.7%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$109.33B
5Y Perf.+45.8%

IRIX vs ATRC vs EW vs HOLX vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IRIX logoIRIX
ATRC logoATRC
EW logoEW
HOLX logoHOLX
SYK logoSYK
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & SuppliesMedical - Devices
Market Cap$18M$1.33B$46.10B$16.97B$109.33B
Revenue (TTM)$51M$552M$6.07B$4.13B$25.12B
Net Income (TTM)$-5M$-5M$1.07B$544M$3.25B
Gross Margin38.0%75.5%78.1%52.8%63.5%
Operating Margin-6.0%-0.4%26.7%17.5%22.4%
Forward P/E428.7x26.6x17.2x19.1x
Total Debt$5M$88M$705M$2.63B$14.86B
Cash & Equiv.$2M$167M$2.94B$1.96B$4.01B

IRIX vs ATRC vs EW vs HOLX vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IRIX
ATRC
EW
HOLX
SYK
StockMay 20May 26Return
IRIDEX Corporation (IRIX)10057.2-42.8%
AtriCure, Inc. (ATRC)10055.0-45.0%
Edwards Lifescience… (EW)100106.7+6.7%
Hologic, Inc. (HOLX)100142.6+42.6%
Stryker Corporation (SYK)100145.8+45.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: IRIX vs ATRC vs EW vs HOLX vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Edwards Lifesciences Corporation is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. ATRC and SYK also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
IRIX
IRIDEX Corporation
The Healthcare Pick

Among these 5 stocks, IRIX doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ATRC
AtriCure, Inc.
The Growth Play

ATRC ranks third and is worth considering specifically for growth exposure.

  • Rev growth 14.9%, EPS growth 74.7%, 3Y rev CAGR 17.4%
  • 14.9% revenue growth vs IRIX's -6.2%
Best for: growth exposure
EW
Edwards Lifesciences Corporation
The Quality Compounder

EW is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 17.6% margin vs IRIX's -10.0%
  • 8.0% ROA vs IRIX's -17.9%, ROIC 15.5% vs -129.9%
Best for: quality and efficiency
HOLX
Hologic, Inc.
The Income Pick

HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.45
  • Lower volatility, beta 0.45, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.45, current ratio 3.75x
  • Lower P/E (17.2x vs 26.6x)
Best for: income & stability and sleep-well-at-night
SYK
Stryker Corporation
The Long-Run Compounder

SYK is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 179.2% 10Y total return vs EW's 125.5%
  • PEG 1.28 vs EW's 3.75
  • 1.2% yield; 34-year raise streak; the other 4 pay no meaningful dividend
Best for: long-term compounding and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthATRC logoATRC14.9% revenue growth vs IRIX's -6.2%
ValueHOLX logoHOLXLower P/E (17.2x vs 26.6x)
Quality / MarginsEW logoEW17.6% margin vs IRIX's -10.0%
Stability / SafetyHOLX logoHOLXBeta 0.45 vs IRIX's 1.16, lower leverage
DividendsSYK logoSYK1.2% yield; 34-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)HOLX logoHOLX+35.3% vs SYK's -24.5%
Efficiency (ROA)EW logoEW8.0% ROA vs IRIX's -17.9%, ROIC 15.5% vs -129.9%

IRIX vs ATRC vs EW vs HOLX vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IRIXIRIDEX Corporation
FY 2024
Retina
57.2%$28M
Cyclo G Six
26.1%$13M
Product and Service, Other
16.7%$8M
ATRCAtriCure, Inc.
FY 2025
Shipping and Handling
100.0%$2M
EWEdwards Lifesciences Corporation
FY 2025
Transcatheter Heart Valves
74.0%$4.5B
Surgical Heart Valve Therapy
17.0%$1.0B
Transcatheter Mitral And Tricuspid Therapies
9.1%$551M
HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

IRIX vs ATRC vs EW vs HOLX vs SYK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLEWLAGGINGATRC

Income & Cash Flow (Last 12 Months)

EW leads this category, winning 3 of 6 comparable metrics.

SYK is the larger business by revenue, generating $25.1B annually — 495.9x IRIX's $51M. EW is the more profitable business, keeping 17.6% of every revenue dollar as net income compared to IRIX's -10.0%. On growth, ATRC holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIRIX logoIRIXIRIDEX CorporationATRC logoATRCAtriCure, Inc.EW logoEWEdwards Lifescien…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…
RevenueTrailing 12 months$51M$552M$6.1B$4.1B$25.1B
EBITDAEarnings before interest/tax-$2M$13M$1.8B$974M$6.3B
Net IncomeAfter-tax profit-$5M-$5M$1.1B$544M$3.2B
Free Cash FlowCash after capex-$3M$54M$1.3B$1000M$4.3B
Gross MarginGross profit ÷ Revenue+38.0%+75.5%+78.1%+52.8%+63.5%
Operating MarginEBIT ÷ Revenue-6.0%-0.4%+26.7%+17.5%+22.4%
Net MarginNet income ÷ Revenue-10.0%-0.8%+17.6%+13.2%+12.9%
FCF MarginFCF ÷ Revenue-5.6%+9.7%+22.0%+24.2%+17.1%
Rev. Growth (YoY)Latest quarter vs prior year+7.8%+14.3%+13.3%+2.5%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+25.0%+101.6%-75.4%-9.2%+56.0%
EW leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

HOLX leads this category, winning 3 of 7 comparable metrics.

At 30.5x trailing earnings, HOLX trades at a 30% valuation discount to EW's 43.7x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs EW's 6.17x — a lower PEG means you pay less per unit of expected earnings growth.

MetricIRIX logoIRIXIRIDEX CorporationATRC logoATRCAtriCure, Inc.EW logoEWEdwards Lifescien…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…
Market CapShares × price$18M$1.3B$46.1B$17.0B$109.3B
Enterprise ValueMkt cap + debt − cash$20M$1.3B$43.9B$17.6B$120.2B
Trailing P/EPrice ÷ TTM EPS-1.91x-109.50x43.69x30.53x33.98x
Forward P/EPrice ÷ next-FY EPS est.428.71x26.58x17.21x19.06x
PEG RatioP/E ÷ EPS growth rate6.17x2.29x
EV / EBITDAEnterprise value multiple73.24x24.47x17.39x19.76x
Price / SalesMarket cap ÷ Revenue0.36x2.49x7.60x4.14x4.35x
Price / BookPrice ÷ Book value/share8.07x2.55x4.53x3.43x4.87x
Price / FCFMarket cap ÷ FCF27.56x34.53x18.44x25.53x
HOLX leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

EW leads this category, winning 5 of 9 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-109 for IRIX. EW carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRIX's 2.21x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs IRIX's 2/9, reflecting strong financial health.

MetricIRIX logoIRIXIRIDEX CorporationATRC logoATRCAtriCure, Inc.EW logoEWEdwards Lifescien…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…
ROE (TTM)Return on equity-108.7%-1.0%+10.4%+11.0%+15.0%
ROA (TTM)Return on assets-17.9%-0.7%+8.0%+6.1%+6.9%
ROICReturn on invested capital-129.9%-0.6%+15.5%+9.4%+11.4%
ROCEReturn on capital employed-48.8%-0.6%+14.0%+8.8%+13.0%
Piotroski ScoreFundamental quality 0–925676
Debt / EquityFinancial leverage2.21x0.18x0.07x0.52x0.66x
Net DebtTotal debt minus cash$2M-$79M-$2.2B$667M$10.8B
Cash & Equiv.Liquid assets$2M$167M$2.9B$2.0B$4.0B
Total DebtShort + long-term debt$5M$88M$705M$2.6B$14.9B
Interest CoverageEBIT ÷ Interest expense0.47x8.00x6.72x
EW leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

SYK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in SYK five years ago would be worth $11,752 today (with dividends reinvested), compared to $1,377 for IRIX. Over the past 12 months, HOLX leads with a +35.3% total return vs SYK's -24.5%. The 3-year compound annual growth rate (CAGR) favors SYK at 0.8% vs IRIX's -23.2% — a key indicator of consistent wealth creation.

MetricIRIX logoIRIXIRIDEX CorporationATRC logoATRCAtriCure, Inc.EW logoEWEdwards Lifescien…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…
YTD ReturnYear-to-date-12.0%-33.1%-6.3%+1.9%-17.8%
1-Year ReturnPast 12 months-9.6%-15.7%+7.1%+35.3%-24.5%
3-Year ReturnCumulative with dividends-54.6%-45.0%-10.2%-8.5%+2.4%
5-Year ReturnCumulative with dividends-86.2%-64.2%-11.5%+16.8%+17.5%
10-Year ReturnCumulative with dividends-90.8%+84.4%+125.5%+124.3%+179.2%
CAGR (3Y)Annualised 3-year return-23.2%-18.1%-3.5%-2.9%+0.8%
SYK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than IRIX's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ATRC's 60.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIRIX logoIRIXIRIDEX CorporationATRC logoATRCAtriCure, Inc.EW logoEWEdwards Lifescien…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 5001.16x0.95x0.64x0.45x0.52x
52-Week HighHighest price in past year$1.65$43.18$87.89$76.04$404.87
52-Week LowLowest price in past year$0.87$26.10$72.30$53.62$284.97
% of 52W HighCurrent price vs 52-week peak+62.4%+60.9%+91.0%+100.0%+70.5%
RSI (14)Momentum oscillator 0–10041.644.053.169.126.6
Avg Volume (50D)Average daily shares traded124K678K4.7M10.3M2.1M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ATRC as "Buy", EW as "Buy", HOLX as "Hold", SYK as "Buy". Consensus price targets imply 95.3% upside for ATRC (target: $51) vs 3.9% for HOLX (target: $79). SYK is the only dividend payer here at 1.18% yield — a key consideration for income-focused portfolios.

MetricIRIX logoIRIXIRIDEX CorporationATRC logoATRCAtriCure, Inc.EW logoEWEdwards Lifescien…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$51.33$97.08$79.00$389.62
# AnalystsCovering analysts19484250
Dividend YieldAnnual dividend ÷ price+1.2%
Dividend StreakConsecutive years of raises34
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.8%+1.9%+4.4%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

EW leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HOLX leads in 2 (Valuation Metrics, Risk & Volatility).

Best OverallEdwards Lifesciences Corpor… (EW)Leads 2 of 6 categories
Loading custom metrics...

IRIX vs ATRC vs EW vs HOLX vs SYK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is IRIX or ATRC or EW or HOLX or SYK a better buy right now?

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -6. 2% for IRIDEX Corporation (IRIX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate AtriCure, Inc. (ATRC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — IRIX or ATRC or EW or HOLX or SYK?

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus Edwards Lifesciences Corporation at 43. 7x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Edwards Lifesciences Corporation's 3. 75x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — IRIX or ATRC or EW or HOLX or SYK?

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +17.

5%, compared to -86. 2% for IRIDEX Corporation (IRIX). Over 10 years, the gap is even starker: SYK returned +179. 2% versus IRIX's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — IRIX or ATRC or EW or HOLX or SYK?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus IRIDEX Corporation's 1. 16β — meaning IRIX is approximately 155% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 2% for IRIDEX Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — IRIX or ATRC or EW or HOLX or SYK?

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -6. 2% for IRIDEX Corporation (IRIX). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — IRIX or ATRC or EW or HOLX or SYK?

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus -18. 3% for IRIDEX Corporation — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus -17. 1% for IRIX. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is IRIX or ATRC or EW or HOLX or SYK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Edwards Lifesciences Corporation's 3. 75x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Hologic, Inc. (HOLX) trades at 17. 2x forward P/E versus 428. 7x for AtriCure, Inc. — 411. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.

08

Which pays a better dividend — IRIX or ATRC or EW or HOLX or SYK?

In this comparison, SYK (1.

2% yield) pays a dividend. IRIX, ATRC, EW, HOLX do not pay a meaningful dividend and should not be held primarily for income.

09

Is IRIX or ATRC or EW or HOLX or SYK better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, IRIX: -90. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between IRIX and ATRC and EW and HOLX and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK pays a dividend while IRIX, ATRC, EW, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IRIX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 22%
Run This Screen
Stocks Like

ATRC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Gross Margin > 45%
Run This Screen
Stocks Like

EW

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Net Margin > 10%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform IRIX and ATRC and EW and HOLX and SYK on the metrics below

Revenue Growth>
%
(IRIX: 7.8% · ATRC: 14.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.